Please assess the completion status of the following clinical trial:

Trial Title: Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Diagnosis of primary systemic amyloidosis~PATIENT CHARACTERISTICS:~* Not pregnant~* Negative pregnancy test~* Able to tolerate an anticoagulation regimen (e.g., 325 mg of aspirin per day, therapeutic warfarin, or low molecular weight heparin)~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~  * Permanent or stable side effects/changes allowed~* Prior chemotherapy, thalidomide, lenalidomide, or steroids for amyloidosis allowed~* More than 4 weeks since prior and no other concurrent cytotoxic chemotherapy or radiotherapy~Exclusion Criteria:~* No secondary or familial amyloidosis~* No multiple myeloma (≥ 30% plasma cells in bone marrow biopsy or lytic bone lesions)~* No prior cumulative doses of oral melphalan \> 200 mg~* No more than one prior course of high-dose melphalan with stem cell transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melphalan Revlimid and Dexamethasone (Type: EXPERIMENTAL): Melphalan Lenalidomide Dexamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).